Harald Burkhardt
Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA).
Koehm M, Foldenauer A, Rossmanith T, Alten R, Aringer M, Backhaus M, Burmester G, Feist E, Kellner H, Krueger K, Müller-Ladner U, Rubbert-Roth A, Tony H, Wassenberg S, Burkhardt H, Behrens F. Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA). J Clin Med 2022; 11
09.12.2022Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA).
09.12.2022J Clin Med 2022; 11
Koehm Michaela, Foldenauer Ann C, Rossmanith Tanja, Alten Rieke, Aringer Martin, Backhaus Marina, Burmester Gerd R, Feist Eugen, Kellner Herbert, Krueger Klaus, Müller-Ladner Ulf, Rubbert-Roth Andrea, Tony Hans-Peter, Wassenberg Siegfried, Burkhardt Harald, Behrens Frank
Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study)
Behrens F, Wassenberg S, Tony H, Rubbert-Roth A, Müller-Ladner U, Lehn A, Krueger K, Kellner H, Herrmann E, Feist E, Burmester G, Backhaus M, Aringer M, Alten R, Rossmanith T, Koehm M, Burkhardt H. Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study). Rheumatology (Oxford) 2021; 60:5318-5328.
03.01.2021Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study)
03.01.2021Rheumatology (Oxford) 2021; 60:5318-5328
Behrens Frank, Wassenberg Siegfried, Tony Hans-Peter, Rubbert-Roth Andrea, Müller-Ladner Ulf, Lehn Annette, Krueger Klaus, Kellner Herbert, Herrmann Eva, Feist Eugen, Burmester Gerd R, Backhaus Marina, Aringer Martin, Alten Rieke, Rossmanith Tanja, Koehm Michaela, Burkhardt Harald
Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting
Alten R, Burkhardt H, Feist E, Krüger K, Rech J, Rubbert-Roth A, Voll R, Elbez Y, Rauch C. Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting. Arthritis Res Ther 2018; 20:1.
02.01.2018Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting
02.01.2018Arthritis Res Ther 2018; 20:1
Alten Rieke, Burkhardt Harald, Feist Eugen, Krüger Klaus, Rech Juergen, Rubbert-Roth Andrea, Voll Reinhard E, Elbez Yedid, Rauch Christiane
Antibodies to the endoplasmic reticulum-resident chaperones calnexin, BiP and Grp94 in patients with rheumatoid arthritis and systemic lupus erythematosus
Weber C, Voll R, Schett G, Burkhardt H, Müller R, Distler J, Graef D, Mielenz D, Sehnert B, Englbrecht M, Haslbeck M, Fürnrohr B. Antibodies to the endoplasmic reticulum-resident chaperones calnexin, BiP and Grp94 in patients with rheumatoid arthritis and systemic lupus erythematosus. Rheumatology (Oxford) 2010; 49:2255-63.
17.08.2010Antibodies to the endoplasmic reticulum-resident chaperones calnexin, BiP and Grp94 in patients with rheumatoid arthritis and systemic lupus erythematosus
17.08.2010Rheumatology (Oxford) 2010; 49:2255-63
Weber Christian K, Voll Reinhard E, Schett Georg, Burkhardt Harald, Müller Rüdiger, Distler Jörg H, Graef Daniela, Mielenz Dirk, Sehnert Bettina, Englbrecht Matthias, Haslbeck Martin, Fürnrohr Barbara G